Autres langues Milestone Pharmaceuticals Inc.

Actions

MIST

CA59935V1076

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 07/05/2024			Varia. 5j.	Varia. 1 janv.
1,74 ^USD	0,00%		+5,45%	+4,19%

08/04	Milestone Pharmaceuticals annonce des données sur l?étripamil démontrant la capacité des patients à gérer eux-mêmes leur TVP récurrente. Les données démontrent la capacité des patients à gérer eux-mêmes les TVP récurrentes, présentées lors de la réunion annuelle de l'American College of Cardiology.	CI
28/03	Milestone Pharmaceuticals soumet à nouveau sa demande de nouveau médicament pour l'étripamil à la FDA	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Milestone® Pharmaceuticals Announces Data Presentations on Etripamil at Heart Rhythm 2024, 2024 Stanford BioDesign Arrhythmia Technologies Retreat, and ISPOR 2024	02/05
Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium	17/04
Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients’ Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting	08/04
Milestone Pharmaceuticals Announces Etripamil Data Demonstrating Patients? Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting	08/04
Milestone® Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference	03/04
Milestone® Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences	01/04
Milestone Pharmaceuticals Resubmits Etripamil New Drug Application to FDA	28/03
Milestone Pharmaceuticals : Corporate Presentation	28/03
Milestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia	28/03
Milestone Pharmaceuticals Inc. Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia	28/03
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update	21/03
Milestone Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
Milestone Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
Milestone Pharmaceuticals : Corporate Presentation	07/03
Milestone® Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference	29/02
Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded Warrants	29/02
Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants	28/02
Milestone Pharma Shares Rise 25% After Plans to Resubmit Etripamil NDA	26/02
Milestone Pharmaceuticals Announces Plan to Resubmit NDA for Etripamil for the Treatment of PSVT	26/02
Milestone Pharmaceuticals Inc. Announces Plan to Resubmit NDA for Etripamil for the Treatment of Psvt	26/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Milestone Pharmaceuticals Inc.

Actions

MIST

CA59935V1076

Autres langues

Filtres